rethinkPeptides Search
Menu
Study breakdown

Anti-NGF Antibody Pain Relief Involves Changes in Endogenous Opioid Peptide Systems

evidence
The takeaway

Anti-nerve growth factor immunoglobulin-induced pain relief was partly mediated through enhanced endogenous opioid peptide signaling, linking NGF antagonism to the opioid pain control system.

Key finding

Anti-nerve growth factor immunoglobulin-induced pain relief was partly mediated through enhanced endogenous opioid peptide signaling, linking NGF anta

What the researchers found

Anti-nerve growth factor immunoglobulin-induced pain relief was partly mediated through enhanced endogenous opioid peptide signaling, linking NGF antagonism to the opioid pain control system.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2011.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
Anti-NGF Antibody Pain Relief Involves Changes in Endogenous Opioid Peptide Systems
What was found?
Anti-nerve growth factor immunoglobulin-induced pain relief was partly mediated through enhanced endogenous opioid peptide signaling, linking NGF antagonism to the opioid pain control system.

Read the original research

Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.

Neuroscience, 193, 452-65

Citation

Hoffman, E M; Zhang, Z; Anderson, M B; Schechter, R; Miller, K E. (2011). Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.. Neuroscience, 193, 452-65. https://doi.org/10.1016/j.neuroscience.2011.06.069